Copeptin in heart failure

References

• Oudejans I, Mosterd A, Bloemen JA, et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail. 2011;13(5):518–527.
   Web of Science ®Google Scholar
• Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev. 2006;11(2):95–107.
   Web of Science ®Google Scholar
• Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–1146.
   PubMed Web of Science ®Google Scholar
• Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3(3):315–322.
   PubMed Web of Science ®Google Scholar
• Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes. 2010;3(6):573–580.
   PubMed Web of Science ®Google Scholar
• Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119(4):515–523.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–1847.
   PubMed Web of Science ®Google Scholar
• Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973;52(9):2340–2352.
   PubMed Web of Science ®Google Scholar
• Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem. 1972;28(3):334–339.
   Google Scholar
• Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112–119.
   PubMed Web of Science ®Google Scholar
• Kasting NW, Mazurek MF, Martin JB. Endotoxin increases vasopressin release independently of known physiological stimuli. Am J Physiol. 1985;248(4 Pt 1):E420–E424.
   Google Scholar
• Passeron A, Dupeux S, Blanchard A. [Hyponatremia: from physiopathology to practice]. Rev Med Interne. 2010;31(4):277–286. French.
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Marchetti J, Corvol P, Menard J, Milliez P. Abnormal regulation of antidiuretic hormone in idiopathic edema. Am J Med. 1979;67(1):67–73.
   Web of Science ®Google Scholar
• Morawiec B, Kawecki D. Copeptin: a new marker in cardiology. J Cardiovasc Med (Hagerstown). 2013;14(1):19–25.
   PubMed Web of Science ®Google Scholar
• Morgenthaler NG. Copeptin: A biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16 Suppl 1:37–44.
   Google Scholar
• Rivier C, Vale W. Interaction of corticotrophin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo. Endocrinology. 1983;113(3):939–942.
   PubMed Web of Science ®Google Scholar
• Milsom SR, Conaglen JV, Donald RA, Espiner EA, Nicholls MG, Livesey JH. Augmentation of the response to CRF in man: relative contributions of endogenous angiotensin and vasopressin. Clin Endocrinol (Oxf). 1985;22(5):623–629.
   Web of Science ®Google Scholar
• Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 2 – clinical physiology. Crit Care. 2004;8(1):15–23.
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, Erzurum SC. Human vascular endothelial cells express oxytocin receptors. Endocrinology. 1999;140(3):1301–1309.
   PubMed Web of Science ®Google Scholar
• Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A. 1997;94(21):11704–11709.
   PubMed Web of Science ®Google Scholar
• Zenteno-Savin T, Sada-Ovalle I, Ceballos G, Rubio R. Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. Eur J Pharmacol. 2000;410(1):15–23.
   Web of Science ®Google Scholar
• Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009;94(1):123–129.
   PubMed Web of Science ®Google Scholar
• Katan M, Morgenthaler NG, Dixit KC, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab. 2007;92(7):2640–2643.
   Web of Science ®Google Scholar
• Uscn Life Science Inc. [homepage on the Internet]. Available from: http://www.uscnk.com/directory/Copeptin(CPP)-0365.htm. Accessed May 6, 2014.
   Google Scholar
• von Haehling S, Papassotiriou J, Morgenthaler NG, et al. Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. Int J Cardiol. 2012;162(1):27–32.
   PubMed Web of Science ®Google Scholar
• Folli C, Consonni D, Spessot M, et al. Diagnostic role of copeptin in patients presenting with chest pain in the emergency room. Eur J Intern Med. 2013;24(2):189–193.
   Web of Science ®Google Scholar
• Dupuy AM, Chastang E, Cristol JP, Jreige R, Lefebvre S, Sebbane M. Analytical performances of the newly developed, fully automated Kryptor Copeptin assay: which impact factor for myocardial infarction rules out in the emergency department? Clin Lab. 2012;58(7–8):635–644.
   Web of Science ®Google Scholar
• Charpentier S, Maupas-Schwalm F, Cournot M, Elbaz M, Botella JM, Lauque D. Combination of copeptin and troponin assays to rapidly rule out non-ST elevation myocardial infarction in the emergency department. Acad Emerg Med. 2012;19(5):517–524.
   Web of Science ®Google Scholar
• Ray P, Charpentier S, Chenevier-Gobeaux C, et al. Combined copeptin and troponin to rule out myocardial infarction in patients with chest pain and a history of coronary artery disease. Am J Emerg Med. 2012;30(3):440–448.
   PubMed Web of Science ®Google Scholar
• Lotze U, Lemm H, Heyer A, Müller K. Combined determination of highly sensitive troponin T and copeptin for early exclusion of acute myocardial infarction: first experience in an emergency department of a general hospital. Vasc Health Risk Manag. 2011;7:509–515.
   PubMedGoogle Scholar
• Günebakmaz O, Celik A, Inanc MT, et al. Copeptin level and copeptin response to percutaneous balloon mitral valvuloplasty in mitral stenosis. Cardiology. 2011;120(4):221–226.
   Web of Science ®Google Scholar
• Mizia-Stec K, Lasota B, Mizia M, et al. Copeptin constitutes a novel biomarker of degenerative aortic stenosis. Heart Vessels. 2013;28(5):613–619.
   Web of Science ®Google Scholar
• Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology. 1992;77(4):662–668.
   PubMed Web of Science ®Google Scholar
• Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107(18):2313–2319.
   Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131(4):1058–1067.
   PubMed Web of Science ®Google Scholar
• Fenske W, Quinkler M, Lorenz D, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome – revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011;96(5):1506–1515.
   Web of Science ®Google Scholar
• Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37(2):145–152.
   PubMed Web of Science ®Google Scholar
• Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007;28(2):219–226.
   PubMed Web of Science ®Google Scholar
• Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66(6):799–808.
   PubMed Web of Science ®Google Scholar
• Zweifel C, Katan M, Schuetz P, et al. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol. 2010,10:34.
   Web of Science ®Google Scholar
• Dong XQ, Huang M, Yang SB, Yu WH, Zhang ZY. Copeptin is associated with mortality in patients with traumatic brain injury. J Trauma. 2011;71(5):1194–1198.
   PubMedGoogle Scholar
• Fenske W, Wanner C, Allolio B, et al. German Diabetes, Dialysis Study Investigators. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol. 2011;22(4):782–790.
   PubMed Web of Science ®Google Scholar
• Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol. 2013;9(4):223–239.
   PubMed Web of Science ®Google Scholar
• Li X, Yang XC, Sun QM, Chen XD, Li YC. Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease. Chin Med J (Engl). 2013;126(5):823–827.
   Web of Science ®Google Scholar
• Velho G, Bouby N, Hadjadj S, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care. 2013;36(11):3639–3645.
   PubMed Web of Science ®Google Scholar
• Bosselmann H, Egstrup M, Rossing K, et al. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study. Int J Cardiol. 2013;170(2):202–207.
   PubMed Web of Science ®Google Scholar
• Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem. 1999;195(1–2):93–98.
   PubMed Web of Science ®Google Scholar
• Goldsmith SR. Vasopressin as vasopressor. Am J Med. 1987;82(6):1213–1219.
   PubMed Web of Science ®Google Scholar
• Fan YH, Zhao LY, Zheng QS, Dong H, Wang HC, Yang XD. Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. Life Sci. 2007;81(4):327–335.
   PubMed Web of Science ®Google Scholar
• Stoiser B, Mörtl D, Hülsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006;36(11):771–778.
   PubMed Web of Science ®Google Scholar
• Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13(1):42–49.
   PubMed Web of Science ®Google Scholar
• Tentzeris I, Jarai R, Farhan S, et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011;13(7):726–733.
   PubMed Web of Science ®Google Scholar
• Miller WL, Hartman KA, Grill DE, Struck J, Bergmann A, Jaffe AS. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart. 2012;98(5):389–394.
   PubMed Web of Science ®Google Scholar
• Khan SQ, Dhillon OS, O’Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115(16):2103–2110.
   PubMed Web of Science ®Google Scholar
• Kelly D, Squire IB, Khan SQ, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail. 2008;14(9):739–745.
   PubMed Web of Science ®Google Scholar
• Voors AA, von Haehling S, Anker SD, et al. OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009;30(10):1187–1194.
   PubMed Web of Science ®Google Scholar
• Neuhold S, Huelsmann M, Strunk G, et al. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem. 2010;56(1):121–126.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Carbonieri E, et al. GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010;12(4):338–347.
   Web of Science ®Google Scholar
• Balling L, Kistorp C, Schou M, et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail. 2012;18(5):351–358.
   PubMed Web of Science ®Google Scholar
• Miller WL, Grill DE, Struck J, Jaffe AS. Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure. Am J Cardiol. 2013;111(6):880–885.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Levin-Iaina N, Malyszko JS, Kozminski P, Koc-Zorawska E, Mysliwiec M. Copeptin and its relation to arteriovenous fistula (AVF) type and NYHA class in hemodialysis patients. Ren Fail. 2011;33(10):929–934.
   PubMed Web of Science ®Google Scholar
• Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008;52(4):266–272.
   PubMed Web of Science ®Google Scholar
• Silva Marques J, Luz-Rodrigues H, David C, G Almeida A, Nunes Diogo A. [Biomarkers of functional class in systolic heart failure: the relevance of copeptin]. Rev Port Cardiol. 2012;31(11):701–710. Portuguese.
   Google Scholar
• Przybylowski P, Malyszko J, Malyszko JS. Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness. Transplant Proc. 2010;42(5):1808–1811.
   Web of Science ®Google Scholar
• Malyszko J, Przybylowski P, Koc-Zorawska E, et al. Copeptin in relation to New York Heart Association class in heart transplant recipients and kidney transplant recipients. Transplant Proc. 2010;42(10):4259–4262.
   Web of Science ®Google Scholar
• Peacock WF, Nowak R, Christenson R, et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011;18(9):947–958.
   PubMed Web of Science ®Google Scholar
• Maisel A, Xue Y, Shah K, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail. 2011;4(5):613–620.
   PubMed Web of Science ®Google Scholar
• Potocki M, Breidthardt T, Mueller A, et al. Copeptin and risk stratification in patients with acute dyspnea. Crit Care. 2010;14(6):R213.
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart. 2009;95(18):1508–1513.
   PubMed Web of Science ®Google Scholar
• Breidthardt T, Irfan A, Klima T, et al. Pathophysiology of lower extremity edema in acute heart failure revisited. Am J Med. 2012; 125(11):1124.e1–1124.e8.
   Web of Science ®Google Scholar
• Lin Q, Fu F, Chen H, Zhu B. Copeptin in the assessment of acute lung injury and cardiogenic pulmonary edema. Respir Med. 2012;106(9):1268–1277.
   PubMed Web of Science ®Google Scholar
• Loncar G, von Haehling S, Tahirovic E, et al. Effect of beta blockade on natriuretic peptides and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: results from the CIBIS-ELD trial. Clin Biochem. 2012;45(1–2):117–122.
   PubMed Web of Science ®Google Scholar
• Miller WL, Hartman KA, Hodge DO, et al. Response of novel biomarkers to BNP infusion in patients with decompensated heart failure: a multimarker paradigm. J Cardiovasc Transl Res. 2009;2(4):526–535.
   Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–1331.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–1343.
   PubMed Web of Science ®Google Scholar
• Alehagen U, Dahlström U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011;305(20):2088–2095.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Welsh P, Whincup PH, Lennon L, Papacosta O, Sattar N. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study. Eur J Heart Fail. 2014;16(1):25–32.
   PubMed Web of Science ®Google Scholar
• Mason JM, Hancock HC, Close H, et al. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. PLoS One. 2013;8(1):e53560.
   PubMed Web of Science ®Google Scholar
• Jarai R, Mahla E, Perkmann T, et al. Usefulness of pre-operative copeptin concentrations to predict post-operative outcome after major vascular surgery. Am J Cardiol. 2011;108(8):1188–1195.
   Web of Science ®Google Scholar
• Nigro N, Müller B, Morgenthaler N, et al. The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases. Swiss Med Wkly. 2011;141:w13270.
   PubMed Web of Science ®Google Scholar
• Christensen HM, Schou M, Goetze JP, et al. Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction. BMC Cardiovasc Disord. 2013;13:80.
   PubMed Web of Science ®Google Scholar